Pleomorphic Adenoma of the Parotid Gland--- Review of 22 Cases

DebaJyoti Roy, Nirupama Moran

1Assistant professor, Department of Otorhinolaryngology, IQ City Medical College and Narayana Multispecialty Hospital, Durgapur, India.
2Senior resident, Department of Otorhinolaryngology, IQ City Medical College and Narayana Multispecialty Hospital, Durgapur, India.

Abstract:
Background and objectives: pleomorphic adenoma is the most frequent benign salivary gland tumour, preferentially diagnosed in the parotid gland. This study was to analyses the outcome of patients with pleomorphic adenoma from Parotid gland in order to evaluate the surgical strategy in our institution.

Materials and Methods: The study was conducted in the department of Otorhinolaryngology, IQ City Medical College and Narayana Multispecialty Hospital, Durgapur, India between November 2014 to November 2016.

Results: The total numbers of cases were 22. Average age group for parotid pleomorphic adenoma was found to be between 31 – 50 years. The number of male patients was 7 and female 15. The pleomorphic adenoma preferentially originated in the right parotid gland (n=22; right 14, left: 8). Primary therapy of the patients were local resection in 5, conservative parotidectomy( Superficial parotidectomy) in 17. Postoperatively 7 patients developed facial weakness which eventually improved during follow-up, 1 patient there was permanent facial weakness due to facial nerve sacrifice. Follow-up periods taken for 6 months.

Conclusion: Pleomorphic adenoma of parotid glands is a benign tumour. Surgery with safety margins is the therapy of choice. Multinodular tumours are prone to recurrent disease.

Keywords: conservative parotidectomy, Pleomorphic adenoma, parotid gland, local resection.

I. Introduction

Pleomorphic adenoma is the most frequent benign salivary gland tumour, preferentially diagnosed in the parotid gland. It occurs in patients of all ages, with the highest incidence reported in the fourth to fifth decades. Histologically, the tumour is characterized by marked morphological diversity, with glandular,myxomatous and solid areas are seen. Seifert et al classified these tumours into cellular type (27-35%), myxoid (stroma rich) type (35-51%) and the classic type (14-37%)3. A capsule is usually present around the tumour, however, this capsule is usually focally thin or absent, particularly with the myxoid subtype and with the larger tumors3,4,5. The tumour grows slowly with long quiescent periods and short periods of rapid growth. It is usually symptomless apart from lump but some may complains of local discomfort. If patient presenting with pain and facial paralysis it must make consider for malignancy. The capsule of compressed normal parotid tissue varies in thickness and the tumour extends into the capsule in a lobulated fashion. This is why shelling the tumour out leads to the risk of local recurrence, which may be in several sites since some of the lobules in the capsule can be left behind5. If the tumour removal includes a cuff of surrounding parotid tissue, recurrence rates are typically less than 2 percent7,8,9,10.

Though pleomorphic adenoma is a benign tumour (Figure-1), if left untreated 5% may become malignant (carcino ma ex pleomorphic adenoma). For this reason, surgical excision is always to be advised1.
This study was to analyses the outcome of patients with pleomorphic adenoma from Parotid gland in order to evaluate the surgical strategy in our institution.

II. Materials And Methods
The study was conducted in the department of Otorhinolaryngology, IQ City Medical College and Narayana Multispecialty Hospital, Durgapur, India between November 2014 to November 2016. All the patients were included in this study were detailed clinical history and physical examination. Demographic data was recorded in terms of age, sex and the site of involvements. Total 22 cases were selected for surgeries. Out of 22 cases, 15 cases were female and 7 cases were male. Based on the clinical and radiological characteristics decisions were taken regarding the types of surgery. Data were grouped and analysed by standard statistical method.

III. Results and Observations
Out of 22 cases, 15(68.18%) cases were female and 7(31.81%) cases were male (Figure-2)

Figure-2: Showing Male and Female ratio

Average age group for parotid pleomorphic adenoma was found to be between 31 – 50 years.

<table>
<thead>
<tr>
<th>AGE IN YEARS</th>
<th>NUMBER AND PERCENTAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=22</td>
</tr>
<tr>
<td>1.0-10</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>2.11-20</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>3.21-30</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>4.31-40</td>
<td>5(22.72%)</td>
</tr>
<tr>
<td>5.41-50</td>
<td>8 (36.36%)</td>
</tr>
<tr>
<td>6.51-60</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>7.61-70</td>
<td>1 (5%)</td>
</tr>
<tr>
<td></td>
<td>Total 22</td>
</tr>
</tbody>
</table>
Table-1 showing age wise involvement.

The pleomorphic adenoma preferentially originated in the right parotid gland (n=22; right 14, left: 8). Swelling was the first finding in all the patients. Associated with pain in 36.36 \%(n=8) Associated with feeling of pressure in 22.72 \%(n=5). Recurrent tumour was recorded in 2 patients, both between age group 40-50 years. Both operated outside the study period (Enucleation).There are 15 swellings were located in the pre-auricular, 6 were in the infra-auricular and 1 in the outer mandibular angle. Primary therapies of the patients were local resection in 5; superficial parotidectomies were done in 17 patients. Post-operatively: Local resection – no one developed facial weakness. But 2 patients back with recurrences. Superficial parotidectomies – 7 patients developed facial weakness which eventually improved during follow-up. 1 patient there was permanent facial weakness due to facial nerve sacrifice (Figure -4). None of the operated patients developed recurrences.

Figure-4 showing postoperatively developing facial palsy

IV. Discussion

Pleomorphic adenoma is a benign epithelial tumour. Complete tumour excision is mandatory; otherwise there is a considerable risk of local recurrence. Surgical treatment planning has to consider the risk of a carcinoma arising in a pleomorphic adenoma. In our study it was found that two patients who were enucleation presented to us with recurrence. Parotid gland (superficial parotidectomy) is adequate treatment for the majority of tumours. Enucleation or extra capsular dissection is acceptable in those rare situations when the tumour is hanging off the inferior pole of the parotid gland, but not otherwise. William et al in their study found that the optimal treatment for pleomorphic adenoma is wide excision with negative margins. The preferred treatment of pleomorphic adenoma of the parotid gland is superficial parotidectomy or total parotidectomy with facial nerve dissection and preservation. J.D Maynard, he carried out 336 parotidectomies for pleomorphic adenoma of the parotid gland, 130 primary pleomorphic adenomas were treated by wide excision of the tumour after identification of the facial nerve. Recurrence occurred in only one patient and, although 20 patients (15 per cent) experienced some degree of facial nerve weakness postoperatively, there was only one case of permanent weakness.

V. Conclusion

Pleomorphic adenoma of parotid glands is a benign tumour. Surgery with safety margins is the therapy of choice. Multinodular tumours are prone to recurrent disease. Partial parotidectomy is an effective treatment for the majority of pleomorphic adenomas; local recurrence is rare and morbidity is low.

References

Pleomorphic Adenoma of the Parotid Gland--- Review of 22 Cases


